Anti-anginal Drug Class List

Drugs in Drug Class: Anti-anginal

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Arthur Grp	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212781-002	Mar 23, 2020	AB	RX	No	No
Mankind Pharma	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212284-002	Feb 12, 2020	AB	RX	No	No
Vkt Pharma	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	214035-002	Jan 19, 2022	AB	RX	No	No
Aurobindo Pharma	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	209081-002	Dec 23, 2022	AB	RX	No	No
Arthur Grp	RANOLAZINE	ranolazine	TABLET, EXTENDED RELEASE;ORAL	212781-001	Mar 23, 2020	AB	RX	No	No

Last updated: July 19, 2026

Anti-anginal Market Dynamics and Patent Landscape: Which Patents Still Block Generic Entry, and Where Revenue Is Most At Risk?

The anti-anginal class spans multiple mechanisms (nitrates, beta-blockers, calcium-channel blockers, and newer agents such as anti-ischemic metabolics). Patent and exclusivity risk is concentrated in (1) branded, fixed-dose combinations and (2) newer molecular entities and controlled/modified-release versions. Most long-established therapies face generic competition and limited remaining exclusivity. The highest forward-looking patent thickets typically come from formulation (extended-release) and method-of-use improvements rather than core pharmacology.

What defines the anti-anginal drug class for patent and exclusivity analysis?

Anti-anginal drug development and patenting usually clusters by pharmacologic mechanism and by product type:

Which anti-anginal mechanisms drive modern patent estates?

• Nitrates and nitrate-related donors (short-acting and long-acting delivery)
• Beta-adrenergic blockers
• Calcium-channel blockers (non-dihydropyridines and dihydropyridines depending on indication)
• Anti-ischemic metabolic agents and late-stage adjunct therapies (e.g., agents used for chronic ischemia or symptom management)

How do drug labels map to patent-relevant claims?

• Symptom control (angina frequency, exercise tolerance)
• Cardiovascular outcomes (reduced ischemic events, angina-related endpoints)
• Formulation claims (controlled release, dose timing, particle/solid-state)
• Combination claims (fixed-dose pairings with distinct dosing schedules)

What matters most for Orange Book and Paragraph IV risk in anti-anginal drugs?

• Whether the approved product is protected by unexpired Orange Book patents tied to:
  • drug substance
  • drug product (formulation/controlled release)
  • method of use (including dosing regimens)
• Whether the FDA-reviewed labeling and patient population align with the method-of-use claims

Which anti-anginal drugs still have meaningful remaining patent exclusivity in the US?

Featured snippet answer: Remaining US exclusivity in anti-anginal is most likely for newer branded controlled-release formulations and post-launch life-cycle patents rather than for first-generation beta-blockers/nitrates/calcium-channel blockers.

Because anti-anginal is a broad class, “still meaningful” depends on the specific product name and NDC. Without a defined target set (single brand vs top sellers vs specific molecule), the safest defensible market-and-patent synthesis is at the class-structure level: where value concentrates and how patent thickets form.

Where patent life-cycle most often preserves brand share

• Modified-release formulations that improve tolerability or dosing adherence
• Fixed-dose combinations that create label-specific dosing regimens
• Solid-state/polymorph and particle-size patents that block “same formulation” generics
• Method-of-use claims tied to specific chronic dosing strategies or patient subgroups

Where generic erosion is fastest

• Immediate-release single-API products with limited formulation differentiation
• Products whose Orange Book listing is sparse or whose listed patents expire first
• Products where method-of-use claims are weakly enforced or easily design-around-able

Market dynamics pattern in anti-anginal

• Demand is cyclical by guideline cycles and payer pressure, with substitution toward lower-cost generics once exclusivity ends
• Brand-to-generic switching often accelerates when tablets/capsule formulations have no controlled-release differentiation
• Payer contracting for older anti-anginal generics is typically throughput- and WAC/AWP-driven; patent leverage has a narrower window unless products are positioned around adherence or tolerability

When does anti-anginal exclusivity end, and how should you model it?

Featured snippet answer: Model anti-anginal exclusivity as two overlapping tracks: (1) regulatory exclusivity (including pediatric and orphan-related if applicable, though anti-anginal is generally not orphan-led) and (2) patent expiration and Orange Book-listed staggered life-cycle patents.

How to model timing for generic entry risk

• Earliest generic launch date is driven by the first unexpired Orange Book patent that blocks approval for the desired labeling
• For fixed-dose and modified-release products, the “last-to-expire” drug product/formulation patent often sets the ceiling even after drug substance patents expire
• Method-of-use patents can delay labeling-specific entry even if the formulation is generically available

Paragraph IV challenge timing in anti-anginal

• Paragraph IV is most common when:
  • Orange Book lists a dense set of formulation and method-of-use patents
  • The branded label includes dosing regimens that are difficult to change without losing claim coverage
• Settlement agreements are often structured around:
  • “at-risk” launch dates
  • carve-outs for certain strengths or dosing regimens
  • agreements to switch to fewer claimed features (e.g., different release profile)

Biosimilar risk in anti-anginal

• Biosimilars are generally not relevant to most anti-anginal therapies because the class is dominated by small molecules.
• Biosimilar risk assessment matters only if a biologic anti-ischemic or symptom-modifying therapy exists within the considered “anti-anginal” scope.

What patents protect anti-anginal drugs: drug substance, drug product, or method of use?

Featured snippet answer: Anti-anginal patent estates frequently hinge on drug product (controlled release, formulation) and method-of-use (dose regimen and symptom control endpoints), with drug substance patents often expiring earlier.

Drug substance patents

• Define the core API composition or specific chemical entities
• Commonly expired or near-expired for older therapies in the class

Drug product patents (formulation, controlled release)

Common claim themes:

• Extended-release matrices
• Coatings controlling dissolution
• Particle engineering and solid-state forms
• Combination tablets with distinct release profiles
• Manufacturing method claims tied to stability and release

Method-of-use patents

Common claim themes:

• Specific dosing schedules (e.g., titration and maintenance regimens)
• Indications tied to chronic stable angina symptom reduction
• Use in combination with other cardiovascular therapies where the regimen is claim-defined

Practical IP implication for generics

• Generics typically succeed quickest by:
  • matching API and strength while using a different release/particle profile if allowed
  • omitting claimed method-of-use language by seeking narrower labeling
• If the Orange Book contains strong drug product or method-of-use patents tied to core labeling, design-around becomes costly.

How strong is the patent estate for key anti-anginal products, and what makes it strong?

Featured snippet answer: Strength correlates with (1) claim density across formulation and method-of-use patents, (2) survival through litigation, and (3) ability of generics to maintain label identity without design-around.

Strength indicators used in diligence

• Number of Orange Book patents per NDA/NDC (patent density)
• Remaining life of the last-to-expire drug product/formulation patent
• Litigation history involving the same patents or same formulation approach
• Whether claims are narrow (easier design-around) or broad (harder)
• History of Section viii paragraph or ANDA amendment patterns showing compliance difficulty

Typical weaknesses in anti-anginal estates

• Overbroad method-of-use claims without clear nexus to the approved regimen
• Product patents that are easier to circumvent with alternative release technology
• Settlement that narrows enforcement to a subset of claims without broad blocking power

Which anti-anginal drugs face the highest generic launch risk after patent cliffs?

Featured snippet answer: Highest generic launch risk comes right after the last blocking Orange Book formulation patent expires for the branded controlled-release or fixed-dose product.

Risk segmentation by product structure

• Single-API immediate-release products: typically lower residual risk due to early generic availability
• Modified-release single-API: higher risk because drug product patents can be numerous and central
• Fixed-dose combinations: highest risk due to intertwined claims across APIs, tablet design, and regimen wording

What to watch for in the FDA pipeline

• ANDAs referencing branded products with “no carve-out” positions on method-of-use claims
• Patent certifications matching narrow subsets of Orange Book patents (signals likely design-around)
• Timing of Paragraph IV notice letters after patent expiry milestones

What patent litigation affects anti-anginal generics: filing, stay, and settlement patterns?

Featured snippet answer: Litigation in anti-anginal follows the standard ANDA framework: Paragraph IV notices trigger infringement suits; courts enter an automatic stay on FDA approval; settlements often convert stays into a scheduled launch date.

Common litigation outcomes that shift market share fast

• Dismissal of infringement claims or findings of invalidity that collapse blocking patents
• Narrow claim construction that enables earlier labeling entry via design-around
• Global settlements that establish multi-product entry schedules

Market impact mechanics

• If a settlement enables “skinny” labeling early, brand share can decline before full generic entry
• If a settlement blocks all strengths, brands retain volume longer until the last patent expires

What is the Orange Book status of anti-anginal drugs, and how is it used in strategy?

Featured snippet answer: Orange Book status is the gating variable for whether generics can get approval to market with the same labeling.

How to interpret Orange Book listings for anti-anginal

• Drug Substance patents set a baseline, but Drug Product and Method of Use frequently control the real blocking effect
• The presence of multiple drug product patents across strengths indicates high implementation specificity for generics
• If method-of-use patents cover core labeled regimens, generics will either:
  • seek narrower labeling
  • or litigate to clear those claims

Why Orange Book reading must be tied to the dosage form

Anti-anginal value is frequently dosage-form dependent:

• sustained-release vs immediate-release
• scored tablet strengths
• fixed-dose tablet release profiles

A generic that is “bioequivalent” on paper may still be blocked by formulation-specific patents.

How do anti-anginal companies defend share: licensing, settlements, and authorized generics?

Featured snippet answer: Anti-anginal brands defend share through (1) life-cycle patenting around release and regimen details, (2) settlements that delay ANDA approvals, and (3) authorized generics in some cases to manage launch economics.

Licensing and settlement patterns that matter

• “Work-around” settlements can allow partial entry while the rest stays blocked
• Licensing can transfer the ability to market earlier strengths or alternate release profiles
• Authorized generics can reduce price erosion while maintaining managed volume

Business rationale in anti-anginal

• Payer and channel leverage makes price cuts visible quickly
• Brands prefer controlled entry to avoid abrupt volume collapse across large formularies

What are the formulation and manufacturing IP barriers for anti-anginal generics?

Featured snippet answer: Manufacturing barriers are most likely where patents cover controlled release technology, stability-related solid-state forms, and specific tablet/coating designs.

Formulation IP hotspots

• Controlled-release matrices and coatings controlling dissolution and absorption timing
• Solid-state form patents tied to process controls
• Particle engineering and mixing/process patents that affect release and bioequivalence

Regulatory and CMC interplay

• If the generic’s formulation differs materially, it may fail to qualify for the same design space or require additional bridging studies
• Even when CMC can be demonstrated, a formulation-specific Orange Book patent can still block approval

How does the anti-anginal competitive landscape change after exclusivity expires?

Featured snippet answer: After exclusivity, anti-anginal competition typically shifts from patent leverage to price and contracting, with quick substitution into generics once formulary barriers fall.

What changes post-expiry

• WAC/AWP compression and payer rebate renegotiation
• Rapid entry by multiple ANDAs once patent cliffs are cleared
• Consolidation among generics in segments with difficult controlled-release manufacturing

What persists even with generic entry

• Adherence positioning for controlled-release products can maintain small brand premiums depending on contracting
• Safety/tolerability differences, if supported by labeling, can slow substitution in narrow subgroups

Key takeaways on anti-anginal market dynamics and patent leverage

1. Remaining patent and exclusivity leverage in anti-anginal concentrates in modified-release and fixed-dose products, where formulation and method-of-use patents are dense.
2. Generic entry risk peaks immediately after the last-to-expire Orange Book formulation and method-of-use patents tied to the marketed strengths.
3. Paragraph IV challenges and settlements follow a repeatable playbook: infringement suits lead to FDA stays, and settlements convert uncertain outcomes into scheduled launch windows.
4. For diligence, the decision variable is not just drug substance expiration, but whether drug product and method-of-use patents cover the exact labeled regimen and dosage form.
5. After cliffs, competition becomes payer-driven with fast price compression, while CMC complexity can limit the speed and breadth of generic entry for controlled-release products.

FAQs

Which anti-anginal drug types are most likely to have long-lived formulation patents?

Modified-release and fixed-dose combination products, particularly where tablet/coating technology and release kinetics are central to the marketed label.

What patent category most often blocks generic entry in anti-anginal?

Drug product (formulation/controlled release) and method-of-use patents tied to labeled dosing regimens and chronic symptom control.

Do anti-anginal settlements usually permit “skinny” labeling early?

Often, settlements can enable partial entry via narrowed labeling or strength-limited launch, depending on how method-of-use and formulation claims are carved.

Are biosimilars relevant to anti-anginal exclusivity risk?

Generally no for typical small-molecule anti-anginal therapies; biosimilar risk applies only if a biologic anti-ischemic therapy exists in the specific drug set under review.

How should CMC differences affect patent strategy for anti-anginal generics?

Even if bioequivalence can be engineered, formulation-specific patents can still block approval if Orange Book-listed claims cover the generic’s release characteristics and solid-state/manufacturing attributes.

References

1. FDA. Approved Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”). U.S. Food and Drug Administration. (Accessed via FDA Orange Book database).
2. FDA. Guidance for Industry: Patent Certifications and Changes to Approved NDA/ANDA Applications Under the Hatch-Waxman Amendments. U.S. Food and Drug Administration.
3. FDA. Approved Drug Products and Drug Submissions (ANDA, 505(b)(1)) Overview. U.S. Food and Drug Administration.